Address:
Division of Oncology
Mail Stop 8056-0029-11
Washington University
660 South Euclid Avenue
St. Louis, MO 63110
11th Floor Mid Campus Center (office)
Admin:
Teresa Weidner
tweidner@wustl.edu
- Non-Hodgkin’s lymphoma
- Hodgkin’s disease
- Chronic lymphocytic leukemia
My research focuses on the design, conduct, and analysis of clinical trials evaluating new treatments for patients with non-Hodgkin (NHL) or Hodgkin lymphoma (HL), including investigator-initiated, pharmaceutical and cooperative group trials. I have been Vice-Chair of the CALGB/Alliance Lymphoma Committee for more than 10 years, where I have served as PI or Co-PI of several Phase II studies and mentored young investigators during trial design and analysis. I serve as the Principal Investigator of the Washington University/Siteman Cancer Center NCTN U10 grant, engaging senior, mid-level, junior investigators and fellows in the National Clinical Trials Network mission. I work closely with the pharmaceutical company SeaGen testing the anti-CD30 based antibody drug conjugate, brentuximab vedotin (BV), for both HL and NHL including efforts to combine BV with chemotherapy and/or PD-1 inhibitors as first line therapy in HL and with lenalidomide in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Our investigator-initiated phase I/dose expansion study of BV and lenalidomide in relapsed DLBCL serves as the experimental arm of an ongoing company-sponsored randomized Phase 3 study. I have ongoing collaborations investigating immunotherapy approaches for lymphoma including 1) the bispecific antibodies (T-cell engagers) mosunetuzumab and glofitimab for R/R B-cell lymphomas, 2) CAR-T cell therapy in R/R DLBCL, 3) personalized neo-antigen vaccines in combination with nivolumab in R/R follicular lymphoma, 4) anti-CD47 antibodies in R/R B-cell lymphomas, and 5) azacytidine or venetoclax in combination with chemotherapy for DLBCL. In addition to my interest in clinical trial development, I have worked closely with other Washington University investigators on exome sequencing of Hodgkin, follicular and transformed large cell lymphoma.
Biosketch
Education
- 1986: MD, Washington University, St. Louis, MO
- 1979: MS in Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA
- 1978: BS in Chemical Engineering, Stanford University, Stanford, CA
Post-Graduate Training
- 1994-1990: Postdoctoral Fellowship in Medical Oncology, Stanford University, Stanford, CA
- 1990-1989: Chief Resident in Internal Medicine, University of California, San Francisco, CA
- 1989-1987: Residency in Internal Medicine, University of California, San Francisco, CA
- 1987-1986: Internship in Internal Medicine, University of California, San Francisco, CA
Academic Positions
- present-2008: Professor of Medicine, Washington University, St. Louis, MO
- 2008-2001: Associate Professor of Medicine, Washington University, St. Louis, MO
- 2001-1994: Assistant Professor, Washington University, St. Louis, MO
Appointments & Committees
- present-2016: Washington University Medical School Admissions Committee
- present-2015: Committee on Research Integrity
- present-2001: Chairman, Quality Assurance and Safety Monitoring Committee, Siteman Cancer Center
- present-1994: Staff Physician, Barnes-Jewish Hospital
- 2001-1999: Protocol Review and Monitoring Committee, Siteman Cancer Center
- 1998: Electronic Medical Record Committee
Board Certification
- 2013: Recertification: Medical Oncology
- 2003: Recertification: Medical Oncology
- 1993: Board Certified: Medical Oncology
- 1989: Diplomate, American Board of Internal Medicine
Honors & Awards
- 2019: Lifetime “Master Physician” Achievement Award from Barnes Jewish Hospital
- 2018: The Leukemia & Lymphoma Society Gateway Chapter Legacy Leadership Award
- 2018-2009: Highest Patient Satisfaction Award, Washington University
- 2017: Teacher of the Year Award in the Hematology-Oncology Fellowship Program, Washington University
- 2016: Washington University Medical School Alumni Achievement Award
- 2016: Health Career Accomplishment Recognition Award from the Healthcare Women’s Business Association
- 2014: Richard L. Schilsky CALGB Achievement Award
- 2009: Koman Professor of Medical Oncology, Washington University
- 1999-1996: American Cancer Society Career Development Award
- 1992: Lymphoma Research Foundation Fellowship
- 1986: Alpha Omega Alpha
- 1978: Phi Beta Kappa
Professional Societies, Organizations & Appointments
- present-2018: Scientific Program Committee – ASCO
- present-2015: Member, NCI Lymphoma Steering Committee
- present-2014: Principal Investigator, NCTN LAPS Grant
- present-2010: National Comprehensive Cancer Network, Non-Hodgkin’s Lymphoma Panel
- present-2010: Scientific Advisory Board of the Lymphoma Research Foundation
- present-2010: AIDS Malignancy Consortium, Data Safety Monitoring Board
- present-2010: Board of Directors, Gateway Chapter Leukemia Lymphoma Society
- present-2003: Vice-Chair, CALGB/Alliance Lymphoma Core Committee
- present-1998: Washington University CALGB Principal Investigator
- present-1998: Member, CALGB Lymphoma Core Committee
- present-1998: CALGB Board of Directors
- present-1995: American Society of Clinical Oncology
- present-1994: American Society of Hematology
- present-1994: Member, Cancer and Leukemia Group B (CALGB)
- present-1989: American College of Physicians
- 2013-2012: Member, ASCO Cancer Education Committee
- 2012-2011: Hodgkin’s Lymphoma Working Group – a Subcommittee of the NCI Lymphoma Steering Committee
- 2010-2007: Scientific Program Committee, American Society of Clinical Oncology
- 2010-2006: Member, CALGB Membership Committee
- 2007-2004: Editorial Board, Journal of Clinical Oncology
- 2005-2003: American Society of Clinical Oncology Program Committee, Adult Leukemia/Lymphoma Subcommittee
- 2002-2000: CALGB Executive Committee